Mode
Home
Research
Clinical Trials Drug Pipeline Weekly Digests
Reference
Conditions Medications
Community
Questions
Text Size
Log in / Sign up
Home › Medications › vemurafenib

vemurafenib

1 published article · Updated continuously

Clinical Trial Landscape

Clinical Trials of vemurafenib

32 trials tracked of vemurafenib: 8 in phase 3 or 4 and 4 with published results. The most-cited published study has 647 citations.

32Trials tracked
8Phase 3 & 4
0Recruiting
4With published results
Phase distribution
Phase 4 1 Phase 3 7 Phase 2 18 Phase 1 5 Other / NA 1
  1. Phase 3 A Study of Atezolizumab Plus Cobimetinib and Vemurafenib Versus Placebo Plus Cobimetinib and Vemurafenib in Previously Untreated BRAFv600 Mutation-Positive Patients With Metastatic or Unresectable Locally Advanced Melanoma Completed · 647 cited
  2. Phase 3 A Study of Vemurafenib in Participants With Metastatic Melanoma Completed · 292 cited
  3. Phase 3 A Study of Vemurafenib Adjuvant Therapy in Participants With Surgically Resected Cutaneous BRAF-Mutant Melanoma Completed · 215 cited
  4. Phase 3 Study Comparing Combination of LGX818 Plus MEK162 Versus Vemurafenib and LGX818 Monotherapy in BRAF Mutant Melanoma Completed · 184 cited
  5. Phase 4 An Extension (Rollover) Study of Vemurafenib in Participants With BRAF V600 Mutation-Positive Malignancies Previously Enrolled in an Antecedent Vemurafenib Protocol Completed
  6. Phase 3 A Study of Vemurafenib (RO5185426) in Comparison With Dacarbazine in Previously Untreated Patients With Metastatic Melanoma (BRIM 3) Completed
Show 26 more trials
  1. Phase 3 A Study Comparing Vemurafenib Versus Vemurafenib Plus Cobimetinib in Participants With Metastatic Melanoma Completed
  2. Phase 3 Dabrafenib Plus Trametinib vs Vemurafenib Alone in Unresectable or Metastatic BRAF V600E/K Cutaneous Melanoma Completed
  3. Phase 2 A Study of Vemurafenib (RO5185426) in Participants With Metastatic or Unresectable Papillary Thyroid Cancer Positive for the BRAF V600 Mutation Completed
  4. Phase 2 BRAF Inhibitor, Vemurafenib, in Patients With Relapsed or Refractory Hairy Cell Leukemia Completed
  5. Phase 2 Phase II Trial of Vemurafenib and Sorafenib in Pancreatic Cancer Completed
  6. Phase 2 A Study Evaluating the Safety and Efficacy of Cobimetinib Plus Atezolizumab in BRAFV600 Wild-type Melanoma With Central Nervous System Metastases and Cobimetinib Plus Atezolizumab and Vemurafenib in BRAFV600 Mutation-positive Melanoma With Central Nervous System Metastases Completed
  7. Phase 2 Phase 2 Study of Neoadjuvant Vemurafenib in Melanoma Patients With Untreated Brain Metastases Completed
  8. Phase 2 A Phase II Randomized Study Comparing the Efficacy and Safety of Targeted Therapy or Cancer Immunotherapy Versus Platinum-Based Chemotherapy in Patients With Cancer of Unknown Primary Site Completed
  9. Phase 2 Vemurafenib, Cobimetinib, Atezolizumab, and Tiragolumab in Treating Patients With High-Risk Stage III Melanoma Completed
  10. Phase 2 Vemurafenib in Treating Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With BRAF V600 Mutations (A Pediatric MATCH Treatment Trial) Completed
  11. Phase 2 A Study of Vemurafenib in Previously Treated Patients With Metastatic Melanoma Completed
  12. Phase 2 Vemurafenib and TIL Therapy for Metastatic Melanoma Completed
  13. Phase 2 LY3022855 With BRAF/MEK Inhibition in Patients With Melanoma Completed
  14. Phase 2 A Study of Biomarker-Driven Therapy in Metastatic Colorectal Cancer (mCRC) Completed
  15. Phase 2 Phase II Safety Study of Vemurafenib Followed by Ipilimumab in Subjects With V600 BRAF Mutated Advanced Melanoma Completed
  16. Phase 2 Vemurafenib With Lymphodepletion Plus Adoptive Cell Transfer & High Dose IL-2 Metastatic Melanoma Completed
  17. Phase 2 A Study of Vemurafenib in Metastatic Melanoma Participants With Brain Metastases Completed
  18. Phase 2 My Pathway: A Study Evaluating Herceptin/Perjeta, Tarceva, Zelboraf/Cotellic, Erivedge, Alecensa, and Tecentriq Treatment Targeted Against Certain Molecular Alterations in Participants With Advanced Solid Tumors Completed
  19. Phase 2 A Study of Vemurafenib in Participants With BRAF V600 Mutation-Positive Cancers Completed
  20. Phase 2 S1406 Phase II Study of Irinotecan and Cetuximab With or Without Vemurafenib in BRAF Mutant Metastatic Colorectal Cancer Completed
  21. Phase 1 A Study of Vemurafenib and GDC-0973 (Cobimetinib) in Participants With BRAFV600E Mutation-Positive Metastatic Melanoma Completed
  22. Phase 1 Vemurafenib Plus Copanlisib in Radioiodine-Refractory (RAIR) Thyroid Cancers Completed
  23. Phase 1 A Study of Vemurafenib (Zelboraf) in Chinese Participants With BRAF V600 Mutation-Positive Unresectable or Metastatic Melanoma Completed
  24. Phase 1 A Pharmacokinetics (PK) Study to Investigate the Effect of Rifampin on PK of Vemurafenib (Zelboraf) Completed
  25. Phase 1 A Pharmacokinetics Study to Investigate the Effect of Vemurafenib on Digoxin in Patients With BRAFV600 Mutation-Positive Metastatic Melanoma Completed
  26. N/A Comparative Effectiveness of Targeted Therapies in BRAF Positive Metastatic Melanoma in the US Completed

Showing the 32 most-cited and recently-updated of 32 trials. Browse the full registry →

Trial data sourced from ClinicalTrials.gov. Counts describe the research landscape and are not a treatment recommendation. Informational only — not medical advice.

HCP Mode — summaries include clinical detail, trial data, and statistical outcomes.
Patient Mode — summaries use plain language, avoiding clinical jargon.
Retrospective analysis identifies molecular correlates of benefit with encorafenib-based therapy in BRAF-mutant melanoma
Dermatology RCT
Retrospective analysis identifies molecular correlates of benefit with encorafenib-based therapy in BRAF-mutant melanoma Melanoma study finds tumor genetics and immune markers may predict treatment benefit
A retrospective exploratory analysis of the phase III COLUMBUS trial in 921 patients with BRAF V600E/K-mutant advanced melanoma found that s…
Patients with advanced melanoma who have higher tumor mutational burden or signs of immune system activity gain the most survival benefit fr…
Apr 4, 2026